Background:
Artemisinin (Qinghaosu), a sesquiterpene lactone, is an anti-malarial drug isolated from the aerial parts of Artemisia annua L. plants[1]. Artemisinin inhibits AKT signaling pathway by decreasing pAKT in a dose-dependent manner. Artemisinin reduces cancer cell proliferation, migration, invasion, tumorigenesis and metastasis and has neuroprotective effects[2].
Artemisinin (Qinghaosu) (25 or 50 μM; 24 hours) concentration-dependently suppresses Aβ25-35 induced cytotoxicity in PC12 cells[1]. Artemisinin (1-100?μM; 24? hours) selectively inhibits cancer cell growth in a dose-dependent manner with IC50 values of 31.30?±?0.73?μM in UMRC-2 cells and 23.97?±?0.92 CAKI-2 cells[2]. Artemisinin (25, 50?μM; 24?hours) suppresses the phosphorylation of AKT in UMRC-2 and CAKI-2 cells in a dose-dependent manner[2].
Artemisinin (gavage; 20?mg/kg/day; for two weeks) suppresses UMRC-2 xenograft tumor growth[2].
参考文献:
[1]. Zeng Z, et al. Artemisinin protects PC12 cells against β-amyloid-induced apoptosis through activation of the ERK1/2 signaling pathway. Redox Biol. 2017 Apr 4;12:625-633.
[2]. Lin SP, et al. Artemisinin Prevents Glutamate-Induced Neuronal Cell Death Via Akt Pathway Activation. Front Cell Neurosci. 2018 Apr 20;12:108.
动态评分
0.0